Bad News for BMS Drug Opdivo Which Falters During Late Stage Lung Cancer Study

Oct 14, 2018 | Bristol-Meyers Squibb, Oncology, Small Cell Lung Cancer

Investment publication Seeking Alpha, reports that Bristol-Myers Squibb’s Opdivo (nivolumab) failed to meet primary end point. The American-based global pharmaceutical company was evaluating Opdivo vs. standard of care (topotecan or amrubicin) in patients with relapsed small cell lung cancer. See the article for more details.


Pin It on Pinterest